| Project/Area Number |
15K10137
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
Miyake Toru 滋賀医科大学, 医学部, 助教 (70581924)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
北村 直美 滋賀医科大学, 医学部, 助教 (30572474)
谷 眞至 滋賀医科大学, 医学部, 教授 (60236677)
清水 智治 滋賀医科大学, 医学部, 准教授 (70402708)
目片 英治 滋賀医科大学, 医学部, 教授 (80314152)
村田 聡 滋賀医科大学, 医学部, 講師 (90239525)
|
|---|
| Research Collaborator |
Pham Minh Ngoc , 大学院生
Kojima MASATSUGU , 助教
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 免疫細胞治療 / 養子免疫 / 抗体療法 / 補助刺激 / 免疫チェックポイント阻害 / 腫瘍免疫 / OX40補助刺激 / 細胞治療 / 免疫治療 / 免疫チェックポイント |
|---|
| Outline of Final Research Achievements |
The main problems of anti-tumor immune cell therapy are followings; there is a limitation of the number of tumor-specific CTLs that can be induced; CTLs transferred to tumor bearing host cannot proliferate in vivo, lose their function, and undergo apoptosis.
We studied to develop a method by which HER2-specific CTL transferred into the HER2-positive breast tumor-bearing mouse can proliferate in the tumor-bearing environment and maintain antitumor activity. As a result, we have demonstrated that tumor Ag-specific CTLs that were generated in vitro in the presence of an MHC-class I-restricted peptide and OX40 co-stimulation are early-differentiated effector T cells and also have the ability to eradicate tumors, and the potential for expansion and maintenance in tumor-bearing host.
|
